opioid-use-disorder
(3)
Pelago
Pelago is a virtual clinic for substance use management, delivering physician-led, evidence-based care for tobacco, alcohol, opioid and other substance use. Founded in 2017 as Quit Genius by three Imperial College London physicians, the company combines cognitive behavioral therapy, medication-assisted treatment and at-home monitoring tools into a program sold to employers, health plans and pharmacy benefit managers. Pelago says it has supported more than 750,000 members and validates its approach with 13 peer-reviewed studies.
Attune Neurosciences, Inc.
Attune Neurosciences is a San Francisco-based, clinical-stage medical device company building what it calls the first wearable, non-invasive focused-ultrasound system for deep brain therapy. Its investigational headband, ATTN201, uses low-intensity transcranial focused ultrasound (tFUS) to reach precise deep-brain targets - like the central medial thalamus - while recording EEG and head movement, aiming to treat sleep and wake disorders, depression, addiction recovery, and other neurological and psychiatric conditions without drugs or surgery.
Ophelia
Ophelia is a New York-based telehealth company making evidence-based opioid use disorder (OUD) treatment available from home. It connects people to licensed clinicians for medication-assisted treatment (buprenorphine/Suboxone), with video visits, on-demand messaging, and care coordination, deliberately removing the friction and stigma of traditional rehab. Founded in 2019 by Zack Gray after he lost a loved one to an overdose, Ophelia focuses heavily on Medicaid and rural populations and has raised roughly $68 million, including a $50M Series B led by Tiger Global in 2021.